News and Press Releases
Neogap secures SEK 87 million to advance clinical development of its personalised immunotherapy
11 February 2026 -- Solna, Sweden -- Neogap Therapeutics AB, a Swedish biotechnology company developing personalised immunotherapy for cancer treatment, has raised SEK 87 million in a financing round led...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 11, 2026
Stiftelsen Cancercentrum Karolinska (CCK) Visionsgatan 56 171 64 Solna, Sweden
PACE launches its third funding round today, supporting innovative projects that tackle resistant bacterial infections posing the greatest threat to global health
1 October 2025 -- Alderley Park, UK -- To stay ahead of the escalating antibiotic resistance crisis, we need bold thinking and transformative innovation. According to the World Health Organization...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 1, 2025
Ryvu Therapeutics Announces Strategic Agreement to Support Clinical Trials for BioNTech’s Investigational Cancer Immunotherapies in Poland
Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clinical programs in Poland Ryvu will leverage its clinical network to...
Category: BioManufacturing, Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 2, 2025
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland
Centauri Therapeutics publishes proof-of-concept data demonstrating activity of a novel bifunctional immunotherapy against Gram-negative bacterial infections
Paper presents the first pre-clinical application of endogenous antibody recruitment to address multi-drug resistant Gram-negative infections Novel bifunctional molecule based on Alphamer platform demonstrated direct, broad-spectrum antibacterial activity in vitro...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: June 10, 2025
iOnctura commences randomized Phase I/II study in non-small cell lung cancer
First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate safety of the combination and explore...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 8, 2025
Campus Biotech Innovation Park Avenue Sécheron 15
1202 Genève
Switzerland
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
7 April 2025 -- California, US -- ImmunityBio, Inc, a leading immunotherapy company, today announced details about its Investor Day program to be held on Tuesday, April 15, 2025, at...
Category: Drug Discovery, Other, Pharmaceutical
Posted: April 7, 2025
Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections
Lead candidate in the ABX-01 programme to progress into first-in-human clinical studies Programme designed to treat Gram-negative bacterial lung infections in the most vulnerable patients. 4 March 2025 -- London,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025
Centauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives
Funding to support further development of lead programme for a novel therapeutic targeting Gram-negative bacteria including Multi-Drug-Resistant strains Optimisation will also support application of the Alphamer® platform across other therapeutic...
Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: November 25, 2024
Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease
19 September 2024 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: September 19, 2024
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage
11 June 2024 -- Lund, Sweden -- Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announced it selected Exothera, a leading...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 11, 2024
Oxford Drug Design and CRUK Scotland Institute awarded MRC grant funding to advance novel cancer therapeutics discovery
Collaboration to use genetically engineered mouse models to validate a new approach to cancer therapy 4 June 2024 - United Kingdom - The CRUK (Cancer Research UK) Scotland Institute and Oxford...
Category: Drug Discovery
Posted: June 10, 2024
Oxford Drug Design Lt,d Oxford Centre for Innovation, New Road, Oxford, OX1 1BY, UK
Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template
9 May 2024 -- Hampton, UK -- Touchlight Genetics, in partnership with the National Physical Laboratory (NPL), have secured funding from Innovate UK under their Innovative Technologies: Nucleic Acid Medicines...
Category: Biotechnology
Posted: May 10, 2024
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T-Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity and Cancer
New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data 6 November 2023 -- Oxford, UK -- Barinthus Biotherapeutics, formerly Vaccitech, a clinical-stage biopharmaceutical company developing novel...
Category: Drug Discovery
Posted: November 27, 2023
